LEADERSHIP
ACESO brings together scientific, clinical, operational, and strategic expertise to guide a focused therapeutic vision for cystic fibrosis care.
01 — OUR LEADERSHIP
Science × Strategy × Patients
The Aceso’s team
Aceso Therapeutics is dedicated to addressing unmet medical needs, particularly for patients who do not adequately respond to existing therapies
MBA
Founder of Aceso Therapeutics, with over 25 years of international leadership experience in healthcare, diagnostics, life sciences, and chemistry. An ESSEC and IIMA graduate, he has led growth and transformation at global companies. Thomas defines the company’s vision and strategy, driven by a passion for improving patients’ lives through innovation and by the values of sports, family, and personal well-being.
PHD
Co-founder, Magali brings over 20 years of experience in rare disease genetics, particularly cystic fibrosis. A recognized scientist with a PhD in Toxicogenomics and author of 33 scientific publications, her career combines academic research, clinical collaboration, and expertise in molecular diagnostics. She leads the company’s scientific vision and research strategy, dedicated to advancing innovative solutions for patients with rare diseases (Cystic Fibrosis).
PHD
Co-founder, Prisca is a trained biochemist who obtained her PhD in 2004 from the Freie Universität Berlin (Germany), focusing on peptide-based inhibitors of protein–protein interactions. She completed a postdoctoral fellowship in peptide vectors for therapeutic delivery at the University of Montpellier before joining the CNRS as a research scientist. Her expertise is supported by 57 publications, 5 book chapters, and 4 patents, with additional experience in myocardial infarction (MI) biotech. Prisca leads the company’s technological strategy and innovation, dedicated to developing advanced therapeutic solutions.
PHD
Senior scientist and biotech executive with a PhD in Molecular Biology and extensive experience in translational research and preclinical development. He has led multidisciplinary projects across academic, clinical, and biotech environments, advancing innovative therapeutic programs from research to application. Sébastien brings strong expertise in project leadership and scientific development within the life sciences sector, and leads the ACT-101 program through its translational and preclinical stages
SCIENTIFIC ADVISORY BOARD
MD, PhD
MD
PharmD, PhD
PhD
Scientific Advisory Board members provide independent scientific guidance and are not involved in the company’s management or operations.
PATIENT-CENTERED. SCIENCE-LED. PURPOSE-DRIVEN.
Connect with ACESO to learn more about our leadership, scientific
vision, and opportunities for collaboration
Headquarters
